On the Record · Usana Health Sciences
Usana Health Sciences acquisitions, on the record
The businesses Usana Health Sciences bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Rise BarWord for word“In 2022, we completed the acquisition of two companies, Rise Bar and Oola Global, LLC "(Oola").” 10-K for 2023 | acquisition | In 2022 | — |
Oola Global, LLCWord for word“In 2022, we completed the acquisition of two companies, Rise Bar and Oola Global, LLC "(Oola").” 10-K for 2023 | acquisition | In 2022 | — |
Business combinations (assets acquired in second quarter of 2022)Word for word“In the second quarter of 2022, the Company acquired assets in business combinations for an aggregate purchase consideration of $ 6,532 in cash and $ 886 in contingent consideration.” 10-K for 2023 | acquisition | In the second quarter of 2022 | $ 6,532 in cash and $ 886 in contingent consideration |
Rise Bar Wellness, Inc. and Oola Global, LLCWord for word“The customer base for our "other" category is comprised of customers of Rise Bar Wellness, Inc. ("Rise") and Oola Global, LLC "(Oola"), which are both businesses we acquired in 2022.” 10-K for 2024 | acquisition | 2022 | — |
Hiya Health Products, LLCWord for word“On December 23, 2024, we acquired a 78.85% controlling ownership interest in Hiya, a leading provider of high-quality children's health and wellness products.” 10-K for 2026 | acquisition | December 23, 2024 | — |
Rise Bar Wellness, Inc.Word for word“In 2022, we acquired Rise and have expanded Rise's product offering, distribution channel, and customer base over the last three years.” 10-K for 2026 | acquisition | 2022 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Goodwill from acquisitions |
|---|---|---|
| 2021-01-02 | $0 | — |
| 2022-01-01 | $0 | $0 |
| 2022-12-31 | $6.5 million | $582,000 |
| 2023-12-30 | $0 | $0 |
| 2024-12-28 | $203.3 million | $127.4 million |
| 2026-01-03 | $0 | — |
Deal filings since 2016
- 2026-10-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-07-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-12-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-12-23 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2020-08-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-07-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-02-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Usana Health Sciences’s annual reports (10-K for 2026, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-03-16. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.